Targeting the FGFR Pathway in Patients with Advanced Solid Tumors.

Chadi Hage Chehade Zeynep Irem Ozay Archana M Agarwal

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

In the phase II FUZE trial targeting the FGFR pathway, Debio 1347 showed limited antitumor activity and manageable toxicity in patients with advanced solid tumors. Results from transcriptomic-based analysis enhanced our understanding of the genomic landscape of FGFR fusion-driven tumors, informing clinical trial design and generating hypotheses for resistance mechanisms.

Keyphrases

phase ii
clinical trial
open label
phase iii
cancer therapy
double blind
single cell
placebo controlled
study protocol
oxidative stress
copy number
rna seq
drug delivery
gene expression
dna methylation
genome wide